Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Atea Pharmaceuticals Inc (AVIR)

Atea Pharmaceuticals Inc (AVIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 254,170
  • Shares Outstanding, K 85,579
  • Annual Sales, $ 0 K
  • Annual Income, $ -168,390 K
  • EBIT $ -162 M
  • EBITDA $ -174 M
  • 60-Month Beta 0.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.61

Options Overview Details

View History
  • Implied Volatility 221.74% ( -27.11%)
  • Historical Volatility 55.15%
  • IV Percentile 62%
  • IV Rank 36.18%
  • IV High 593.81% on 05/16/25
  • IV Low 10.80% on 08/26/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 422
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 3,547
  • Open Int (30-Day) 1,437

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.38
  • Low Estimate -0.45
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +14.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.45 +20.98%
on 05/15/25
3.08 -3.57%
on 05/02/25
+0.02 (+0.68%)
since 04/30/25
3-Month
2.45 +20.98%
on 05/15/25
3.29 -9.73%
on 03/24/25
-0.06 (-1.98%)
since 02/28/25
52-Week
2.45 +20.98%
on 05/15/25
4.14 -28.35%
on 09/17/24
-0.64 (-17.73%)
since 05/28/24

Most Recent Stories

More News
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

AVIR : 2.97 (+0.68%)
COYA : 5.33 (-0.04%)
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals Issues Statement Regarding Director Nominations

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025

AVIR : 2.97 (+0.68%)
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

AVIR : 2.97 (+0.68%)

Business Summary

Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 3.15
2nd Resistance Point 3.10
1st Resistance Point 3.03
Last Price 2.97
1st Support Level 2.91
2nd Support Level 2.86
3rd Support Level 2.79

See More

52-Week High 4.14
Fibonacci 61.8% 3.50
Fibonacci 50% 3.30
Fibonacci 38.2% 3.10
Last Price 2.97
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
OSZAR »